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Abstract: Fixed-dose combination tablets have become an important therapy option for patients 
infected with the human immunodeficiency virus. Fixed-dose combination rilpivirine-tenofovir-
emtricitabine is a recently approved therapy option that has been extensively studied within the 
treatment-naïve population. When compared with efavirenz-based therapy, improved tolerability 
with rilpivirine-based therapy was balanced by higher rates of virologic failure to provide similar 
overall efficacy rates within the intention-to-treat analysis. As a result,   providers will need to 
balance the potential for improved tolerability with fixed-dose combination rilpivirine-tenofovir-
emtricitabine against a higher potential for virologic failure, particularly among patients with 
baseline viral loads above 100,000 copies/mL. Current treatment guidelines have recommended 
that fixed-dose combination rilpivirine-tenofovir-emtricitabine be an alternative therapy option 
for treatment-naïve patients and advise caution in those patients with high viral loads at baseline. 
Similar to other non-nucleoside reverse transcriptase inhibitor-based regimens, there are a number 
of drug interaction concerns with fixed-dose combination rilpivirine-tenofovir-emtricitabine 
that will necessitate monitoring and, in some cases, appropriate management. Additionally, 
the emergence of drug resistance to fixed-dose combination rilpivirine-tenofovir-emtricitabine 
has been well documented in clinical studies and close attention will be necessary in order to 
protect current and future therapy options. Overall, fixed-dose combination rilpivirine-tenofovir-
emtricitabine is poised to provide an important therapy option for patients when appropriately 
applied.
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Introduction
Antiretroviral therapy has evolved over the past two decades into a highly efficacious, 
well tolerated, and conveniently dosed group of therapies. Clinical studies of treatment-
naïve patients demonstrate virologic suppression rates above 80% for many of the new 
treatment regimens.1–3 In order to meet and maintain these high virologic suppression 
rates, strict medication adherence is necessary.4,5 Combination products, particularly 
among the nucleoside reverse transcriptase inhibitor class of agents, have become a stan-
dard of care to reduce pill burden and potentially improve adherence.6,7 However, since 
antiretroviral therapy is composed of a minimum of three active agents, patients may still 
require the administration of multiple tablets, regardless of the availability of nucleoside 
reverse transcriptase inhibitor combination tablets. This has changed with the creation of 
single-tablet regimens. The fixed-dose combination of efavirenz-tenofovir-emtricitabine 
was the first available daily-dosed single tablet that provided a complete antiretroviral 
regimen.8,9 Since its approval, fixed-dose combination efavirenz-tenofovir-emtricitabine 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
61
REVIEw
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/HIV.S25149HIV/AIDS - Research and Palliative Care 2012:4
has become an attractive and highly prescribed therapy for 
treatment-naïve patients due to strong efficacy data, good 
tolerability, and its low pill burden.6,7,10,11 The development of 
additional single-tablet regimens continues to be sought as a 
result of concerns about toxicity, resistance, and teratogenic-
ity risks with the efavirenz component of fixed-dose com-
bination efavirenz-tenofovir-emtricitabine.12–14 Fixed-dose 
combination rilpivirine-tenofovir-emtricitabine represents 
a more recently approved single-tablet regimen.15 Similar to 
fixed-dose combination efavirenz-tenofovir-emtricitabine, 
fixed-dose combination rilpivirine-tenofovir-emtricitabine 
contains tenofovir and emtricitabine, while the efavirenz 
component is replaced by rilpivirine. To date, fixed-dose com-
bination rilpivirine-tenofovir-emtricitabine has demonstrated 
strong efficacy data and good tolerability and is poised to 
provide a valuable therapy option for human immunodefi-
ciency virus (HIV)-infected patients.1,3 This paper reviews 
the efficacy, pharmacokinetics, tolerability, drug interaction 
potential, and resistance concerns with fixed-dose combi-
nation rilpivirine-tenofovir-emtricitabine. Given that the 
rilpivirine component of this fixed-dose combination is most 
recently available, we discuss this agent in more detail in the 
context of a fixed-dose combination.
Pharmacology
Fixed-dose combination rilpivirine-tenofovir-emtricitabine is 
composed of three active antiretroviral agents, ie,   rilpivirine 
25 mg (rilpivirine hydrochloride 27.5 mg), tenofovir 
disoproxil fumarate 300 mg   (tenofovir   disproxil 245 mg), 
and emtricitabine 200 mg.16   Dosage and   administration 
characteristics of this fixed-dose   combination are shown in 
Table 1.17 Consistent with   current therapy   recommendations 
for treatment-naïve patients, this combination spans two 
major classes of antiretroviral agents.6,7   Rilpivirine is a dia-
rylpyrimidine non-nucleoside reverse   transcriptase inhibitor 
(NNRTI).18 Similar to other NNRTIs,   rilpivirine inhibits 
viral DNA polymerization by binding to the hydrophobic 
pocket near the active site of reverse   transcriptase.19 As a 
  diarylpyrimidine NNRTI, rilpirivine is commonly referred 
to as a “next-generation” or “second-generation” NNRTI. 
Agents from this subclass possess a more flexible dihedral 
angle between the aniline ring and cyanovinyl moiety when 
compared with first-generation agents.7,20 This   characteristic 
allows for binding to multiple modes within the highly 
flexible NNRTI binding site of reverse   transcriptase and 
potentially leads to an improved resistance profile, although 
currently   available clinical study data with rilpivirine have 
placed this advantage into question.1,3
Table 1 Administration and place in therapy17,71
Dosage and administration •  One tablet by mouth once daily
•  Administer with a meal
Dosage form Tablets (purplish-pink, capsule-shaped, 
film-coated)
Strengths Each tablet contains:
•  25 mg of rilpivirine
•  300 mg of TDF
•  200 mg FTC
Dosage adjustments Renal impairment:
•    Do not use in patients with moderate 
to severe renal impairment (creatinine 
clearance ,50 mL per minute). Separate 
agents to accommodate dosage 
adjustments necessary for TDF and FTC
Hepatic impairment:
•    No adjustment required for patients with 
mild or moderate hepatic impairment 
(Child-Pugh Classes A and B)
•    Not been studied in patients with severe 
hepatic impairment (Child-Pugh Class C)
Important adverse effect 
concerns that may  
require monitoring
Rash, renal dysfunction, losses in bone 
mineral density, depressive disorders
Recommended place in 
therapy per antiretroviral 
treatment guidelines
Alternative therapy option for NNRTI-
based antiretroviral therapy
•    Caution recommended in patients with 
baseline viral load .100,000 copies/mL
Abbreviations:  NNRTI,  non-nucleoside  reverse  transcriptase  inhibitor;  FTC, 
emtricitabine; TDF, tenofovir disoproxil fumarate.
Tenofovir disoproxil fumarate is a nucleotide reverse 
transcriptase inhibitor.21 Following absorption, this   compound 
is converted to tenofovir by diester hydrolysis and then 
  subsequently phosphorylated to form tenofovir diphosphate.22 
The addition of a phosphate group is the key structural 
  difference between a nucleoside and nucleotide, although 
clinically these drug classes are considered to be largely 
equivalent. Tenofovir diphosphate inhibits HIV reverse 
transcriptase by competing with the natural substrate deoxy-
adenosine 5′-triphosphate for incorporation into viral DNA, 
leading to termination of viral DNA growth.22 Tenofovir is 
active against both HIV-1 and HIV-2 and also has activity 
against hepatitis B virus.23,24
Emtricitabine is a nucleoside reverse transcriptase 
  inhibitor.25 Emtricitabine is the (-) enantiomer of a thio 
analog of cytidine and, unlike other cytidine analogs, has 
a fluorine in the 5-position.26 The molecular structure of 
emtricitabine is highly similar to another antiretroviral agent, 
lamivudine. In clinical practice, these agents are commonly 
considered to be interchangeable in terms of efficacy and 
safety.6,7,27 Emtricitabine also has activity against HIV-1, 
HIV-2, and hepatitis B virus.25,28
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Clinical pharmacokinetics
The pharmacokinetic characteristics of each of the components   
of fixed-dose combination rilpivirine-tenofovir-emtricitabine 
are presented in Table 2.21,22,29–32 The pharmacokinetics of each 
agent supports once-daily   dosing. The plasma elimination 
half-lives are approximated as   follows: rilpivirine 48 hours; 
tenofovir 17 hours; and   emtricitabine 10 hours.22,29–31,33 
The intracellular elimination half-lives of tenofovir and 
  emtricitabine are significantly longer and approximated as 
follows: tenofovir 150 hours and emtricitabine 39 hours.31 
As a result, this fixed-dose   combination can be conveniently 
dosed on a once-daily basis.
When fixed-dose combination rilpivirine-tenofovir-
emtricitabine was administered with food (400 kcal and 
13 grams of fat) in healthy subjects, rilpivirine, tenofovir, and 
emtricitabine exposures were bioequivalent to the administra-
tion of the individual tablets. When the fixed-dose combina-
tion was administered to healthy subjects in the fasted state, 
rilpivirine and emtricitabine concentrations were approxi-
mately 25% higher when compared with administration of 
the individual tablets.16,34 As a result of these differences, it 
is recommended that fixed-dose combination rilpivirine-ten-
ofovir-emtricitabine be administered with a meal.16 However, 
no specific meal type has been recommended. Rilpivirine 
should not be administered with a high protein meal, such as 
protein-rich nutritional drinks, because exposures are reduced 
by 50%.17,35 The solubility and subsequent systemic absorp-
tion of rilpivirine is pH-dependent, as demonstrated by a 
significantly increased bioavailability when given in an acidic 
environment. When coadministered with acid suppressants, 
significant reductions in drug absorption were observed.36 
As a result, fixed-dose combination rilpivirine-tenofovir-
emtricitabine should not be coadministered with proton pump 
inhibitors. H2 antagonists may be coadministered with this 
fixed-dose combination if spaced appropriately, as discussed 
in the drug interaction section.16
The components of fixed-dose combination rilpivirine- 
tenofovir-emtricitabine undergo different routes of 
  elimination. Rilpivirine primarily undergoes oxidative 
metabolism through cytochrome P450 (CYP) 3A, while 
both tenofovir and emtricitabine are eliminated via a mixture 
of glomerular filtration and active tubular secretion.16,22,30,31 
Both tenofovir and emtricitabine require dosage adjustment 
in patients with a creatinine clearance below 50 mL per min-
ute while rilpivirine does not.16,21,25,37 Due to this disparity, 
fixed-dose combination rilpivirine-tenofovir-emtricitabine 
should not be administered to patients with a creatinine 
clearance below 50 mL per minute and the components 
should be separated to accommodate the necessary dosage 
adjustments. None of the components of this fixed-dose 
combination require dosage adjustment in patients with mild 
or moderate hepatic impairment.16 There are insufficient 
data about dosing and safety in patients with severe hepatic 
impairment.
Single-tablet regimens
Currently, there are two single-tablet regimen products that 
are commercially available, and the antiretroviral components 
are efavirenz-tenofovir-emtricitabine and rilpivirine-tenofo-
vir-emtricitabine. Coformulation has significantly reduced 
the overall pill burden and improved the convenience of 
taking antiretroviral therapy. The majority of data regarding 
single-tablet regimens focus mainly on fixed-dose combina-
tion efavirenz-tenofovir-emtricitabine because it has been 
available since 2006. Nonetheless, the data available on 
fixed-dose combination efavirenz-  tenofovir-emtricitabine 
are helpful in understanding the potential benefits of 
using a fixed-dose combination of rilpivirine-tenofovir-
emtricitabine.
Several studies have demonstrated that switching to 
fixed-dose combination efavirenz-tenofovir-emtricitabine 
was generally effective in maintaining virologic suppression 
in patients who had an undetectable viral load at the time of 
switching therapy.38,39 The proportion of patients achieving 
virologic suppression was not significantly   different among 
patients receiving fixed-dose combination efavirenz-tenofovir-
emtricitabine compared with patients who received more 
complex antiretroviral regimens.39,40 These effects were seen 
out to 48 weeks in most studies and up to 96 weeks in one 
study.38 Given the potency of most antiretroviral agents, it 
is unsurprising that single-tablet regimen products achieve 
a similar frequency of virologic suppression compared with 
more complex antiretroviral regimens. Outcomes that may 
differentiate single-tablet regimen regimens from antiretro-
viral regimens with higher complexity include quality of life, 
adherence, patient preference, perceived medication regimen 
complexity, and tolerability.
In the ADONE study, health-related quality of life improved 
during the course of the study.38 Specifically, the difference in 
the quality of life measure was significantly improved after 
24 weeks of switching to fixed-dose combination efavirenz-
tenofovir-emtricitabine compared with baseline.38 Based on 
these data, single-tablet regimens appear to be beneficial 
for improving quality of life. However, when comparing 
the quality of life of single-tablet regimen recipients with 
that of patients who remained on their original   antiretroviral 
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  regimens, there may not be a meaningful change.39 In a trial of 
virologically suppressed HIV-infected patients randomized to 
either switch to fixed-dose combination efavirenz-tenofovir-
emtricitabine or maintain their current antiretroviral regimen, 
quality of life measures did improve from baseline in either 
group.39 However, changes in these quality of life measures 
did not differ significantly between groups.39
In the studies that have evaluated adherence, there appears 
to be a high proportion of patients adhering to single-tablet 
regimens through 48 weeks of therapy.38 There was also a 
higher preference for single-tablet regimens over original 
antiretroviral regimens, and patients perceived that single-
tablet regimens were easier to follow than more complex 
treatment regimens.39 The tolerability of fixed-dose combina-
tion regimens will depend heavily on the components of the 
single-tablet regimen. The studies that have been performed 
thus far have been with fixed-dose combination efavirenz-
tenofovir-emtricitabine, and the majority of adverse effects 
were related to efavirenz use.38–40 While the overall propor-
tion of adverse events was low, there did appear to be a 
higher proportion of psychiatric symptoms, nervous system 
symptoms, and skin/tissue disorders among single-tablet regi-
men recipients compared with patients who did not modify 
their antiretroviral regimen.39 For the rilpivirine-containing 
single-tablet regimen, it is unclear if the frequency of adverse 
events will differ.
One interesting outcome of single-tablet regimen medi-
cation use is hospitalizations. Compared with patients using 
antiretroviral regimens that contain two or more pills per day, 
single-tablet regimen recipients were more likely to achieve 
optimal adherence thresholds and the risk of hospitalization 
was 25% lower.7 As more fixed-dose combination products 
emerge on the market, ancillary health outcomes, like hos-
pitalizations, associated with single-tablet regimen use will 
need to be evaluated for each product. The majority of studies 
evaluating single-tablet regimen products have focused on 
populations that are either treatment-experienced or virologi-
cally suppressed and switching to a single-tablet regimen 
product. Outcomes for viremic patients who are initiating a 
single-tablet regimen product should be evaluated. Given that 
fixed-dose combination rilpivirine-tenofovir-emtricitabine 
is only approved for treatment-naïve individuals, the treat-
ment outcomes of single-tablet regimens in treatment-naïve 
individuals will need to be assessed.
Efficacy
Rilpivirine has been evaluated in two Phase III studies, 
ie, ECHO (a Phase III randomized study of the efficacy 
of rilpivirine compared with efavirenz) and THRIVE 
(a   randomized Phase III study of the efficacy of rilpivirine 
compared with efavirenz in HIV-infected patients using either 
tenofovir-  emtricitabine, zidovudine-lamivudine, or abacavir-
lamivudine).1,3 In the ECHO study, patients were exclusively 
prescribed tenofovir-emtricitabine as the nucleoside reverse 
transcriptase inhibitor backbone.3 In the THRIVE study, 
providers could choose between tenofovir-emtricitabine, 
lamivudine-  zidovudine, or abacavir-lamivudine for the nucle-
oside reverse transcriptase inhibitor backbone.1 Sixty percent 
of patients in the THRIVE trial were given tenofovir-
  emtricitabine as their background nucleoside reverse tran-
scriptase inhibitor regimen.1 For this reason, this review will 
first concentrate on the ECHO study because it exclusively 
studied a regimen consistent with the components of fixed-
dose combination rilpivirine-tenofovir-emtricitabine.
The ECHO trial was a randomized, double-blind, compar-
ative study of rilpivirine versus efavirenz in treatment-naïve 
patients infected with HIV-1.3 The primary objective of the 
study was to show noninferiority between a rilpivirine-based 
and efavirenz-based antiretroviral regimen. The primary end-
point was the proportion of patients who achieved a viral load 
of ,50 copies/mL or maintained a viral load ,50 copies/mL 
after 48 weeks of treatment. Secondary endpoints included 
pharmacokinetics, safety, immune response, and emergence 
of drug resistance. Participants were individuals $18 years of 
age who were infected with HIV-1, were treatment-naïve, and 
had a baseline viral load .5000 copies/mL. Randomization 
was stratified by baseline viral load (#100,000, #500,000, 
and .500,000 copies/mL).
After 1:1 randomization, the intention-to-treat analysis 
included 346 patients who were assigned to receive rilpivirine 
and 344 who received efavirenz-based therapy. At 48 weeks 
of treatment, 83% of patients in both groups had a confirmed 
virologic response, ie, a difference of 0.1% (95% confidence 
interval [CI] 0.1 [-5.5% to 5.7%]). Although the overall 
intention-to-treat outcomes were similar, the reasons for 
treatment failure differed between the treatment groups. 
More virologic failures for the efficacy endpoint (patients 
who never had virologic suppression or experienced virologic 
rebound) occurred with rilpivirine (38 patients [11%] with ril-
pivirine versus 15 patients [4%] with efavirenz). In contrast, 
more patients in the efavirenz group discontinued therapy 
and were considered a treatment failure due to adverse 
events. Specifically, 19 patients (7%) in the efavirenz group 
discontinued therapy due to an adverse event as compared 
with six patients (2%) in the rilpivirine group. The majority 
of adverse events leading to treatment discontinuation with 
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efavirenz were central nervous system effects. In a sensitivity 
analysis that excluded patients who discontinued therapy for 
reasons other than virologic failure, response rates were 86% 
(287/333) and 94% (285/303) for the rilpirivine and efavirenz 
groups, respectively (difference -7.9%, 95% CI -12.5% 
to -3.2%). The immunologic response was similar between 
the treatment groups, with a mean change in absolute CD4 
count of 196 cells/µL (95% CI 179–212) for rilpivirine and 
182 cells/µL (95% CI 165–198) for efavirenz (P = 0.13).
For the purpose of the 96-week analysis, data from the 
ECHO and THRIVE studies were pooled.41 Although the 
majority of patients in this pooled analysis used tenofovir-
emtricitabine as their nucleoside reverse transcriptase 
inhibitor backbone regimen, there were patients using 
abacavir-lamivudine or zidovudine-lamivudine. The overall 
virologic response was 77.6% in both the rilpivirine and efa-
virenz treatment groups [95% CI (-4.4, 4.4)]. Immunologic 
response was also similar between groups and consistent 
with the 48-week ECHO data.
Again, although overall response rates were similar 
between groups, there were more virologic treatment failures 
in the rilpivirine group and more patients who discontinued 
therapy due to toxicity in the efavirenz group. For patients 
who entered the study with a baseline viral load .100,000 
copies/mL, virologic failure was more common in the 
  rilpivirine group. There was no difference in virologic failure 
shown for patients who entered the study with a baseline viral 
load #100,000 copies/mL.
Safety
Overall, the components of fixed-dose combination ril-
pivirine-tenofovir-emtricitabine demonstrate a favorable 
safety profile. The safety of rilpivirine has largely been 
judged based upon its comparison with efavirenz in clini-
cal study.1,3 As highlighted in the efficacy section, overall 
adverse event rates were lower with rilpivirine, and signifi-
cantly fewer patients discontinued rilpirivine therapy due 
to toxicity when compared with efavirenz. The main driver 
for these differences was central nervous system toxicity, 
a known and relatively common side effect of efavirenz.1,3 
Although rilpivirine still has some risk for central nervous 
system toxicity (including headache, depressive disorders, 
and insomnia) it occurs significantly less often. Another 
important difference displayed in the ECHO and THRIVE 
studies was the difference in lipid effects between rilpivirine 
and efavirenz.1,3 Previous data show that efavirenz can cause 
significant increases in low-density lipoprotein, high-density 
lipoprotein, and total cholesterol.42–44 In clinical study, the 
effects of rilpivirine on the serum lipid profile were minimal. 
Grade 2 or higher changes in lipids and triglycerides occurred 
in less than 6% of rilpivirine-treated patients.1,3 Grade 2 lipid 
changes occurred in roughly 10%–20% of efavirenz-treated 
patients. Liver function tests were similar between rilpivirine 
and efavirenz treatment, with #3% of patients experienc-
ing a grade 3 or 4 elevation in aspartate transaminase or 
alanine transaminase.1,3,44 Five percent of rilpivirine-treated 
patients experienced a grade 1 elevation in serum creati-
nine as compared with #1% with efavirenz-based therapy. 
The mean change was 0.09 mg/dL (range -0.20 mg/dL to 
0.62 mg/dL). When increases in serum creatinine occurred, 
they most commonly occurred during the first month of 
therapy and persisted for the entire 48 weeks of therapy, and 
no subjects discontinued therapy due to increases in serum 
creatinine.41 The mechanism of this effect remains unknown 
and the clinical impact appears to be minimal according to 
the available data.
Other side effects observed with rilpivirine in clinical 
study include nausea and rash, both of which occurred 
in #3% of patients.1,2,41 Rilpivirine is associated with a dose-
dependent increase in the QTc interval.25 At the approved 
dose of 25 mg, increases in the QTc interval appear to be 
minimal and are not expected to result in clinically adverse 
effects in patients without pre-existing cardiac conditions. At 
higher doses, the QTc prolongation effect is more pronounced 
and patients who are overdosed with rilpivirine should have 
electrocardiographic monitoring performed.25
The principal toxicity associated with use of tenofovir 
is nephrotoxicity.45 The most common form is proximal 
tubular toxicity characterized by electrolyte wasting and 
serum creatinine elevations. Fanconi syndrome and acute 
renal failure have been documented which, in some cases, 
have led to irreversible renal dysfunction.46–49 Clinical studies 
have shown the overall incidence of nephrotoxicity due to 
  tenofovir to be ,1%; however, small and gradual reductions 
in kidney function have more commonly been shown in clini-
cal studies.50 Outside of the controlled setting of a clinical 
study, the true rates of tenofovir-induced nephrotoxicity 
appear to be higher. Numerous case reports and case series 
have been published to document this.46–48,51,52 Monitoring 
of renal function is recommended for patients who are pre-
scribed a tenofovir-containing regimen. Particular attention 
should be paid to patients who have existing risk factors for 
tenofovir-induced nephrotoxicity. These risk factors include 
underlying renal dysfunction, older age, concurrent use of 
nephrotoxic medications, concurrent use of protease inhibi-
tors, low body weight, and low CD4 count.53–56
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Reductions in bone mineral density have also been 
documented in tenofovir-treated patients. Randomized 
clinical trials show that this effect occurs more commonly 
when patients are treated with tenofovir as compared with 
a regimen that does not contain tenofovir.57 As a result, it is 
recommended that consideration be given to assessing bone 
mineral density in tenofovir-treated patients with risk factors 
for osteoporosis or bone loss.
Emtricitabine has one of the strongest safety profiles 
when compared with other antiretroviral agents, and is 
generally considered to have minimal risk of toxicity.58,59 In 
clinical study, the most common adverse effects observed 
in antiretroviral regimens that included emtricitabine were 
headache, diarrhea, nausea, fatigue, dizziness, depression, 
insomnia, abnormal dreams, rash, abdominal pain, asthenia, 
increased cough, and rhinitis.60 However, it is important to 
note that it is difficult to discern whether these adverse effects 
were directly caused by emtricitabine or the coadministered 
antiretroviral agents. Hyperpigmentation and/or skin dis-
coloration is a unique adverse effect that has been observed 
with emtricitabine but this effect occurs predominantly in 
children.61
Safety data with the combination product, fixed-dose 
combination rilpivirine-tenofovir-emtricitabine are limited  , 
although expected to be similar to what is observed when the 
individual agents are administered. As a result, mild adverse 
effects that may occur include gastrointestinal toxicities 
(nausea, vomiting, diarrhea), headache, and insomnia. More 
concerning adverse effects that require patient monitoring 
may include rash, renal dysfunction, loss of bone mineral 
density, and depressive disorders. To date, there are no toxic-
ity data to suggest that adverse effect risks with fixed-dose 
combination rilpivirine-tenofovir-emtricitabine are different 
to those of the individual agents.
Resistance
Resistance associated with tenofovir and emtricitabine will 
not be discussed in this paper and are reviewed elsewhere.62 
The resistance profile of rilpivirine is unique relative to other 
NNRTIs because it exhibits in vitro activity against both 
wild-type and drug-resistant HIV-1 isolates.63   Rilpivirine 
displays potent activity against HIV-1strains that are 
resistant to older NNRTIs like efavirenz and nevirapine.6 
At the present time, rilpivirine is only approved for use in 
patients that are treatment-naïve. However, the activity of 
rilpivirine against HIV-1 isolates with diminished activity 
against first-generation NNRTIs may still be important to 
consider due to transmitted resistance risks. Approximately 
5%–10% of treatment-naïve patients acquire HIV   infection 
with transmitted drug resistance and these patients experi-
ence a higher frequency of virologic failure when compared 
with patients who are transmitted drug-sensitive virus.64,65 
As a result, rilpivirine may be an attractive option for 
treatment-naïve patients with transmitted drug resistance 
to other NNRTIs.
In ECHO, there were some differences regarding viro-
logic failure.3 Virologic failures with resistance occurred 
in 13% of patients in the rilpivirine treatment arm and 6% 
in the efavirenz group.3 There were 53 patients (40 in the 
rilpivirine group and 13 in the efavirenz group) who expe-
rienced virologic failure and had resistance data available 
at the time of failure. Among these patients, the frequency 
of virologic failure with any treatment-emergent NNRTI 
resistance-associated mutation was similar between rilpi-
virine and efavirenz groups (65% versus 62%, respectively).3 
The most common treatment-emergent NNRTI resistance-
associated mutation in the rilpivirine group was the E138K 
mutation (69%), followed by K101E (19%) and Y181C 
(19%).3 There was a significant difference in the propor-
tion of patients who experienced virologic failure with 
any treatment-emergent International AIDS Society-USA 
  (IAS-USA) nucleoside/nucleotide reverse transcriptase 
inhibitor resistance-associated mutation.3 Specifically, the 
frequency of M184I was 71% and 25% in rilpivirine and 
efavirenz patients, respectively.3
In the THRIVE study,1 there appeared to be nearly a 
two-fold difference in the proportion of patients   experiencing 
virologic failure with any treatment-emergent   IAS-USA 
nucleoside/nucleotide reverse transcriptase inhibitor 
resistance-associated mutation (64% of rilpivirine patients 
compared with 33% of efavirenz patients).1 Among patients 
in the rilpivirine group experiencing virologic failure, the 
most common treatment-emergent NNRTI resistance-
associated mutations were E138K (77%), K101E (73%), 
V189I (15%), and H221Y (15%).1 Among the IAS-USA 
nucleoside/  nucleotide reverse transcriptase   inhibitor 
  resistance-associated mutations identified, the overall 
  frequencies of the M184V and/or I mutations were 86% 
and 60% for patients in the rilpivirine and efavirenz groups, 
respectively, who experienced virologic failure.1
A major resistance concern regarding antiretroviral resis-
tance to NNRTI agents is the issue of cross-resistance. Patients 
who experienced virologic failure in the rilpivirine groups of 
the ECHO and THRIVE studies with evidence of phenotypic 
resistance to rilpivirine had evidence of cross-resistance to 
efavirenz, etravirine, and nevirapine.1,3,66   Specifically, of the 
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31 rilpivirine-treated patients who experienced virologic 
failure and developed phenotypic resistance to rilpivirine, the 
frequencies of cross-resistance to etravirine, efavirenz, and 
nevirapine were 90%, 87%, and 45%,   respectively.3 Given 
that rilpivirine is a drug that is approved for treatment-naïve 
individuals, the issue of cross-resistance may deter its use 
in practice. Efavirenz, nevirapine, and etravirine have been 
used in patients who are treatment-experienced, and the 
antecedent use of rilpivirine in a treatment-naïve individual 
may limit the use of other NNRTI agents if virologic failure 
and phenotypic resistance occurs.
Drug interactions
Drug interactions with tenofovir and emtricitabine are 
described elsewhere.62 This review will focus on drug 
interactions associated with the rilpivirine component of 
fixed-dose combination rilpivirine-tenofovir-emtricitabine. 
Like most NNRTIs, rilpivirine is metabolized through the 
CYP isoenzyme system. It is both a substrate and inducer 
of CYP3A4.18,67 Rilpivirine is primarily metabolized by 
CYP 3A4. However, CYP2 C19, 1A2, and 2C8/9/10 are also 
involved. There are also some inductive effects associated 
with rilpivirine use.68 Specifically, rilpivirine is a moderate 
inducer of CYP 2C19 and 3A4 and has subtle induction 
effects on CYP 1A2 and 2B6.68 As a result of these effects on 
CYP isoenzymes and the necessity for an acidic gastric pH 
for absorption, there are a number of drug interactions associ-
ated with the use of the rilpivirine component of fixed-dose 
combination tenofovir-emtricitabine-rilpivirine. Select drug 
interactions with rilpivirine are represented in Table 3.
Drug interactions associated with rilpivirine use can be 
categorized as agents that should never be coadministered 
with rilpivirine, agents requiring adjustment or monitoring, 
and agents that require no intervention. An abbreviated list 
of drug interactions associated with rilpivirine use is found 
in Table 2. There are a number of agents that should not be 
coadministered with rilpivirine. The most notable are proton 
pump inhibitors, due to increases in gastric pH and reduction 
in rilpivirine concentrations.16 Additionally, anticonvulsants 
and antimycobacterials with CYP-inductive effects should be 
Table 2 Pharmacokinetic characteristics
Pharmacokinetic parameter Rilpivirine Tenofovir Emtricitabine
Oral bioavailability Unknown 25% 93%
Protein binding 99.7% ,0.7% ,4%
Elimination pathway Hepatic Renal Renal
Elimination half-life Approximately 48 hours Approximately 17 hours Approximately 10 hours
Predominant elimination pathway Hepatic (CYP 3A) Renal Renal
Abbreviation: CYP, cytochrome P450.
avoided with rilpivirine, because concentrations of rilpivirine 
may be decreased.16 Macrolide antibiotics like clarithromycin 
and erythromycin should be avoided due to CYP inhibition.16,68 
Where possible, alternative macrolide agents like azithromy-
cin should be utilized. Antacids and H2 receptor antagonists 
should be used with caution, and administration should be 
spaced out from rilpivirine administration.16,68 While there 
have not been studies evaluating this interaction, medications 
that prolong the QTc interval should be used with caution 
because there is a risk of QTc prolongation with rilpivirine 
at higher doses. It is unclear if the use of rilpivirine and a 
QTc prolonging medication would result in an accentuated 
risk of QTc prolongation. Electrocardiographic monitoring 
of high-risk patients using QTc prolonging medications and 
rilpivirine may be considered.
Of note, a significant interaction occurs when   switching 
from efavirenz to rilpivirine. The long half-life of efavirenz 
may be concerning when switching to rilpivirine, because 
efavirenz concentrations persist for weeks after drug discon-
tinuation and efavirenz induces the metabolism of rilpivirine. 
Pharmacokinetic differences were observed in a study of 
20 healthy patients who received rilpivirine for 14 days 
followed by a washout period and subsequently received 
efavirenz for 14 days followed by rilpivirine for 28 days.69 
All rilpivirine pharmacokinetic exposures were significantly 
lower after efavirenz exposure compared with rilpivirine use 
prior to efavirenz exposure.69 A switch study was performed 
in HIV-infected patients with undetectable viral loads using 
efavirenz-tenofovir-emtricitabine who sought to switch 
to rilpivirine-tenofovir-emtricitabine due to intolerance.70 
The average trough plasma rilpivirine concentration was 
52 ng/mL two weeks after switching   therapy.70 For weeks 
4–12, the average trough plasma rilpivirine concentration was 
66–84 ng/mL.70 In the clinical trials that evaluated the efficacy 
of rilpivirine, trough concentrations were 50–80 ng/mL.1,3 
While the trough concentrations in the switch study did not 
fall below this range, it is unclear if patients may be at risk for 
subtherapeutic concentrations of rilpivirine in the presence of 
other medications that affect rilpivirine concentrations, like 
H2 receptor antagonists or antacids. Of note, the efavirenz 
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Table 3 Abbreviated drug interactions associated with rilpivirine
Concomitant medication Comments
Medications that should not be coadministered with rilpivirine
Anticonvulsants: carbamazepine, oxcarbazepine,  
phenobarbital, phenytoin
Strong CYP enzymatic induction may result in significant decreases in rilpivirine plasma 
concentrations
Antimycobacterials: rifampin and rifabutin Strong CYP enzymatic induction may result in significant decreases in rilpivirine plasma 
concentrations.
Rilpivirine AUC, Cmin and Cmax decreased by 46%, 49%, and 35%, respectively, when used 
concomitantly with rifabutin.
Rilpivirine AUC, Cmin and Cmax decreased by 80%, 89%, and 69%, respectively, when used 
concomitantly with rifampin
Proton pump inhibitors Changes in gastric pH leading to subsequent decreases in rilpivirine exposure.
Rilpivirine AUC and Cmin decrease by 40% and 33%, respectively, when omeprazole 
coadministered
Efavirenz AUC of rilpivirine decreased by 70% in presence of efavirenz.
Important pharmacokinetic implications when switching from efavirenz to rilpivirine. May extend 
to other NNRTI agents with persistent inductive effects on CYP system
Macrolide antibiotics: clarithromycin,  
erythromycin
May result in increased exposure to rilpivirine through inhibition of CYP 3A. Consider use of 
azithromycin, where possible
Medications requiring adjustment or added monitoring when coadministered with rilpivirine
Ketoconazole Inhibition of CYP 3A isoenzymes may result in increased rilpivirine plasma concentrations  
(Cmax and Cmin increased by 30% and 76%, respectively) and decreased concentrations of 
ketoconazole (Cmax and Cmin decreased by 15% and 65%, respectively).
Monitor for breakthrough fungal infections. Other antifungal agents may be evaluated for usage
H2 receptor antagonists Use with caution because H2 receptor antagonists increase the gastric pH.
H2 receptor antagonists and rilpivirine should be spaced out. H2 receptor antagonists should be 
administered 12 hours before rilpivirine or 4 hours after rilpivirine ingestion
Antacids Antacids change gastric pH. Administer antacids 2 hours before or 4 hours after rilpivirine dose.
Methadone AUC of R- and S-methadone decreased by 16% in the presence of rilpivirine. Cmin of both R- and 
S-methadone decreased by about 21%. Monitor for signs of methadone withdrawal. May need to 
adjust dose
Antiarrhythmics Potential for decreased concentrations of rilpivirine
Medications known to prolong QT interval Potential pharmacodynamic interaction with other QT prolonging medications
Tenofovir Rilpivirine pharmacokinetics virtually unchanged in presence of tenofovir. Tenofovir 
pharmacokinetics slightly elevated (Cmin 24% higher) in presence of rilpivirine. Consider 
monitoring serum creatinine
Medications requiring no dosage adjustment or intervention
Didanosine Coadminister on an empty stomach
Darunavir/ritonavir No dosage adjustment recommended. However, rilpivirine AUC is 130% higher with darunavir/
ritonavir coadministration
Lopinavir/ritonavir No dosage adjustment recommended. However, rilpivirine AUC is 52% higher with lopinavir/
ritonavir coadministration
Atorvastatin No dosage adjustment recommended
Acetaminophen No dosage adjustment recommended
Ethinyl estradiol Subtle increases in AUC, Cmin and Cmax of ethinyl estradiol. No dosage adjustment necessary
Sildenafil No dosage adjustment recommended
Abbreviations:  AUC,  area  under  the  concentration-time  curve;  Cmax,  peak  plasma  concentration;  Cmin,  trough  plasma  concentration;  CYP,  cytochrome  P450; 
NNRTI, non-nucleoside reverse transcriptase inhibitor.
concentrations remained above the IC50 for 4 weeks after the 
switch to rilpivirine occurred.
Place in therapy
The vast majority of clinical data with fixed-dose combina-
tion rilpivirine-tenofovir-emtricitabine have emerged from 
  studies performed in the treatment-naïve patient   population. 
As a result, this is the patient population that will most 
  commonly be prescribed fixed-dose combination rilpivirine-
tenofovir-emtricitabine. To date, fixed-dose combination 
rilpivirine-tenofovir-emtricitabine has not been adequately 
studied in patients with existing antiretroviral drug resis-
tance and is not officially indicated for use in treatment-
experienced patients. Despite this, rilpivirine may remain 
a sensitive therapy option in patients who have developed 
resistance to first-generation NNRTI agents and future study 
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may demonstrate a role for rilpivirine in this group. Patients 
with transmitted NNRTI resistance may be a particular target 
population for fixed-dose combination rilpivirine-tenofovir-
emtricitabine.
The role of fixed-dose combination rilpivirine-tenofovir-
emtricitabine has not been assessed in each antiretroviral 
treatment guideline to date. The United States Department of 
Health and Human Services antiretroviral treatment guidelines 
have recommended that fixed-dose combination rilpivirine-
tenofovir-emtricitabine be considered as an alternative option 
for NNRTI-based therapy. Fixed-dose combination efavirenz-
tenofovir-emtricitabine continues to be the preferred NNRTI for 
most patients, unless specific adverse event risks, such as preg-
nancy, preclude its use. Because patients who entered clinical 
study with a baseline viral load .100,000 copies/mL were more 
likely to experience virologic failure with   rilpivirine-based 
therapy, caution is recommended when using fixed-dose 
combination rilpivirine-tenofovir-emtricitabine in patients with 
high viral loads (.100,000 copies/mL). Equally concerning 
is the higher rate of drug resistance exhibited after rilpivirine 
failure and the subsequent rate of phenotypic cross-resistance to 
etravirine, nevirapine, and efavirenz. Virologic failure and sub-
sequent drug resistance with rilpivirine appears to limit future 
NNRTI therapy options more uniformly when compared with 
patients who experience virologic failure and drug resistance 
to other NNRTI agents.
When compared with the current standard of care, the 
advantage of rilpivirine in clinical study was its safety and 
tolerability. As a result, this is likely to be the greatest advan-
tage of rilpivirine over existing therapy options, especially 
efavirenz. Given that efavirenz-based therapy continues to 
be the preferred NNRTI therapy option as per treatment 
guidelines, it is likely that fixed-dose combination rilpivirine-
tenofovir-emtricitabine will fill an important need as transi-
tional therapy in patients prescribed fixed-dose combination 
efavirenz-tenofovir-emtricitabine who are unable to tolerate 
adverse effects attributed to efavirenz. For example, if patients 
experience persistent central nervous system toxicity with 
fixed-dose combination efavirenz-tenofovir-emtricitabine, 
fixed-dose combination rilpivirine-tenofovir-emtricitabine 
is likely to represent an attractive therapy option, particu-
larly when their HIV viral load is #100,000 copies/mL at 
the time of the switch. To date, there has been a small study 
to evaluate the safety and efficacy of switching patients from 
fixed-dose combination efavirenz-tenofovir-emtricitabine to 
fixed-dose combination rilpivirine-tenofovir-emtricitabine. 
Data from this study have demonstrated reliable efficacy 
and improved tolerability after the switch, but more data 
are   necessary to ensure virologic efficacy after the switch, 
  particularly when considering the pharmacokinetic drug 
interaction that occurs between efavirenz and rilpivirine 
within the first couple weeks after the switch.69 Another 
important advantage of fixed-dose combination rilpivirine-
tenofovir-emtricitabine over fixed-dose combination 
efavirenz-  tenofovir-emtricitabine is safety during pregnancy. 
Efavirenz is a pregnancy category D agent while rilpivirine 
is a pregnancy category B agent.35,71,72 When considering 
therapy for female patients of childbearing potential, fixed-
dose combination rilpivirine-tenofovir-emtricitabine may be 
a preferred therapy option under certain circumstances.
Summary
Single-tablet regimens represent an enormous step 
forward in the objective of providing safe, effective, and 
conveniently dosed antiretroviral therapy to HIV-infected 
patients. Fixed-dose combination rilpivirine-tenofovir-
emtricitabine has been shown to provide a high degree 
of virologic efficacy and safety in clinical study and will 
be an important therapy option for some patients. When 
compared with the current standard of care, concerns 
over increased risk for virologic failure and drug resis-
tance, particularly among patients with high viral loads, 
will limit its widespread use in the HIV population. Due 
to the unique resistance profile of rilpivirine relative to 
first-generation NNRTI agents, fixed-dose combination 
rilpivirine-tenofovir-emtricitabine may prove to have 
an important therapeutic role for patients with existing 
antiretroviral resistance, but clinical studies are currently 
lacking in this patient population. For now, the most likely 
role for fixed-dose combination rilpivirine-tenofovir-
emtricitabine is to provide an important role as a switch 
therapy for patients experiencing adverse effects on the 
current NNRTI standard of care.
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